Navigation Links
Neuropathy Association Research Grants Advance the Understanding of Diabetic Neuropathy and Autoimmune Neuropathies

NEW YORK, Sept. 22 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--the leading national non-profit organization dedicated to finding cures for peripheral neuropathies--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Dennis Paul, Ph.D. and co-principal investigator, Harry J. Gould, M.D., Ph.D. of Louisiana State University Health Sciences Center New Orleans and Glaucia C. Furtado, Ph.D. of Mount Sinai School of Medicine--were chosen from thirteen applicants involved in neuropathy research at medical institutions across North America.

Drs. Dennis Paul and Harry Gould--co-investigators on the proposal, Sodium Channels, Sodium Pumps, Inflammation, and Diabetic Neuropathy--are investigating the concomitant role of diabetes and inflammation in the development of diabetic neuropathy. They are hopeful that by studying the biological and physical manifestations of diabetic neuropathy--and specifically, the role of nerve cell death by lysis (or bursting)--they will better understand the pathogenesis of one of the most common, and debilitating, complications of diabetes.

Dr. Paul notes, "Understanding the mechanism of nerve cell survival after inflammatory or neuropathic insult will lead to new treatments and preventive strategies for diabetic neuropathy."

Dr. Glaucia Furtado's proposal, Role of CCR7 in Peripheral Neuropathy, is based on the hypothesis that the lack of CCR7--protein receptors normally found on white blood cells (or WBCs) of the immune system--induces an autoimmune demyelinating neuropathy. CCR7 receptors are responsible for guiding migration of WBCs to and within lymph tissues, where they initiate an immune response.

Dr. Furtado explains, "Besides providing new clues for how the immune system works, this study will help us identify therapeutics that block the development of autoimmune neuropathies."

Thomas H. Brannagan, III, M.D., the Association's medical advisor affirms, "We continue to invest in critical research that builds on our understanding of neuropathy's many forms, hopeful that our investments will lead to more effective treatment and cures."

About Peripheral Neuropathy

Peripheral neuropathy is one of the most common chronic diseases in the U.S., affecting more than 20 million Americans. Neuropathy results from injury to the peripheral nerves--the motor, sensory and autonomic nerves--connecting the spinal cord to the muscles, skin, blood vessels and internal organs. It usually affects the hands and feet, causing weakness, numbness, lack of coordination or pain.

Approximately 30% of neuropathies are "idiopathic," meaning of an unknown cause; 30% are caused by diabetes. Other causes include autoimmune disorders, tumors, heredity, nutritional deficiencies, infections, trauma, and toxins.

About The Neuropathy Association

The Neuropathy Association is the leading national nonprofit organization providing neuropathy patient support and education, advocating for patients' interests, and supporting critical research. The Association has more than 50,000 members and supporters and a nationwide network of 135 patient support groups, 5 chapters, and 12 Neuropathy Centers of Excellence.

For information about peripheral neuropathy and The Neuropathy Association, visit

Contact Tina Tockarshewsky at (212) 692-0380

SOURCE The Neuropathy Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
2. First-Time National Poll Confirms Neuropathy Hits Millions in Their Prime
3. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
4. Gene Therapy Improves Diabetic Neuropathy in Study
5. "Electric Socks" for Neuropathy??
6. ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
7. Doctors Issue New Neuropathy Test Guidelines
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
10. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
11. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: